356 related articles for article (PubMed ID: 26673352)
21. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E
Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
23. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Gil T; Marreaud S; Daugaard G; Skoneczna I; Collette S; Lorent J; de Wit R; Sylvester R
J Clin Oncol; 2012 Jan; 30(2):191-9. PubMed ID: 22162575
[TBL] [Abstract][Full Text] [Related]
26. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
[TBL] [Abstract][Full Text] [Related]
27. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Jones R; Crabb S; Chester J; Elliott T; Huddart R; Birtle A; Evans L; Lester J; Jagdev S; Casbard A; Huang C; Madden TA; Griffiths G
BJU Int; 2020 Aug; 126(2):292-299. PubMed ID: 32336008
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
[TBL] [Abstract][Full Text] [Related]
30. A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.
Xu N; Zhang XC; Xiong JP; Fang WJ; Yu LF; Qian J; Zhang L
BMC Cancer; 2007 Jun; 7():98. PubMed ID: 17559681
[TBL] [Abstract][Full Text] [Related]
31. Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function.
Sella A; Kovel S
Int Braz J Urol; 2012; 38(1):49-56. PubMed ID: 22397786
[TBL] [Abstract][Full Text] [Related]
32. [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Helke C; May M; Hoschke B
Aktuelle Urol; 2006 Sep; 37(5):363-8. PubMed ID: 17004181
[TBL] [Abstract][Full Text] [Related]
33. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.
Bellmunt J; de Wit R; Albanell J; Baselga J
Eur J Cancer; 2001 Nov; 37(17):2212-5. PubMed ID: 11677109
[TBL] [Abstract][Full Text] [Related]
34. Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma.
Mitsuzuka K; Yamashita S; Namiki S; Yamada S; Sato K; Saito H; Kaiho Y; Ito A; Nakagawa H; Arai Y
Int J Urol; 2014 Nov; 21(11):1114-9. PubMed ID: 24962105
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R;
Ann Oncol; 2017 Jul; 28(7):1517-1522. PubMed ID: 28419193
[TBL] [Abstract][Full Text] [Related]
36. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
[TBL] [Abstract][Full Text] [Related]
39. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
40. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment.
Bamias A; Lainakis G; Kastritis E; Antoniou N; Alivizatos G; Koureas A; Chrisofos M; Skolarikos A; Karayiotis E; Dimopoulos MA
Oncology; 2007; 73(5-6):290-7. PubMed ID: 18477854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
